Disseminated tuberculosis infection and paradoxical reaction during antimycobacterial treatment related to TNF-alpha blocker agent Infliximab

Disseminated tuberculosis infection and paradoxical reaction during antimycobacterial treatment related to TNF-alpha blocker agent Infliximab

Tumor necrosis factor (TNF)-alpha inhibitors play an important role in the treatment of immun-mediated diseases such as Crohn's disease. But they also have been related to increased risk for disseminated Mycobacterium tuberculosis infections and paradoxical response to antimycobacterial treatment. Here we report a disseminated tuberculosis case and a paradoxical response to treatment after rece...

Prolonged paradoxical reaction to anti-tuberculous treatment after discontinuation of TNF-alpha- blocker therapy with adalimumab. Rare clinical documentation

In the past decades, tumor necrosis factor alpha (TNF-a) antagonist has been a milestone in the treatment of many chronic inflammatory diseases. TNF antagonist can increase patients' susceptibility to many different kinds of infections especially those requiring granuloma formations despite regular performance of Screening for latent tuberculosis infection (LTBI). We report 2 cases of patients ...

Successful Treatment of Refractory Behçet's Disease with the TNF-α Blocker Infliximab

Disseminated Salmonella typhimurium infection secondary to infliximab treatment.

To the Editor: We read with interest the review by Ellerin et al on infections and anti–tumor necrosis factor (anti-TNF) therapy (1), as well as the article by Netea et al reporting 2 cases of Salmonella enterica septicemia secondary to treatment with adalimumab and infliximab (2). Netea and colleagues also demonstrated decreased interferonproduction and inhibition of Toll-like receptor 4 expre...

Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis.

Six of 284 patients treated with infliximab developed active tuberculosis. Four (67%) of these patients had a paradoxical response to antituberculous therapy. Physicians should be aware of the increased risk of a paradoxical response in this population and should consider the use of corticosteroids when a paradoxical reaction is suspected.